(Health Korea News / Yu Ji-in) Yuhan Corporation announced on the 20th through a public disclosure that it had signed a contract with Gilead Sciences to supply HIV treatment raw pharmaceutical ingredients (HIV API) worth 107.66965 billion won. The contract amount is approximately 5.79% of last year’s sales (1.859 trillion won). The contract period is from September 20, 2024 to September 30, 2025.
The supply contract seems to have been signed for the development of Gilead’s HIV (human immunodeficiency virus, AIDS) treatment ‘Sunlenca (ingredient name: lenacapavir)’. Yuhan Chemical, a subsidiary of Yuhan Corporation, is the raw material supplier for Sunlenca, and only Gilead and Yuhan Chemical produce the raw material for Sunlenca. Sunlenca is a long-acting drug that has the advantage of preventing AIDS when administered twice a year, and recently recorded a 100% prevention rate in phase 3 clinical trials.
On the 12th (local time), Gilead released the main analysis results of the phase 3 clinical trial ‘PURPOSE 1, 2 study’ that evaluated the effectiveness of pre-exposure prophylaxis (PrEP) using Sunlenca.
Copyright © Health Korea News. Unauthorized reproduction and redistribution prohibited.
Source: www.hkn24.com
